Novo completed the acquisition of KabaFusion from Pritzker Private Capital.

Novo, a healthcare investment firm, completed the acquisition of KabaFusion, a provider of essential acute, chronic, and enteral home infusion therapies, from Pritzker Private Capital, a private equity firm. Financial terms were not disclosed. "We have been extremely impressed with the pace of growth and service orientation of KabaFusion, which is a testament to their leading clinical knowledge in immunoglobulin therapies and patient-first approach. The investment in KabaFusion fits well with Novo Holdings' overall ambition of creating long-term value and making a positive impact on health, science, and society," Abhijeet Lele, Novo Senior Partner and Head of US Principal Investments.